Table 2 Key structural characteristics and major treatment pathway differences a of European cost-effectiveness model adaptations
Country | Model features |
|---|---|
Scotland | ● Patient simulation for buccal midazolam comparison |
● Parents/carers only give a single dose | |
● Taken to hospital if ambulance called | |
Wales | ● Patient simulation for buccal midazolam comparison |
● Allows for second doses of treatment under emergency care plans | |
● Taken to hospital if ambulance called | |
● Chance of inpatient admission is 100% for patients suffering multiple seizures | |
● Additional chance of admission to intensive care for patients suffering multiple seizures | |
Germany | ● Allows for second doses to be administered |
● Patient may not necessarily be taken to hospital after ambulance call-out | |
Spain | ● Parents/carers only give a single dose |
● Taken to hospital if ambulance called | |
France | ● Allows for second doses to be administered |
● Patient may not necessarily be taken to hospital after ambulance call-out | |
Italy | ● Parents/carers only give a single dose |
● Taken to hospital if ambulance called | |
Switzerland | ● Allows for second doses to be administered |
● Patient may not necessarily be taken to hospital after ambulance call-out |